产前无细胞DNA筛查显性单基因病的进展:当前临床实施进展与未来方向的综述
产前cfDNA筛查已从非整倍体扩展到亚染色体拷贝数变异,但用于显性单基因病(常由新发变异引起)的筛查在普通产科人群中仍未充分利用。本文综述多基因panel产前cfDNA筛查显性单基因病的最新数据与经验,指出其可补充影像学和标准cfDNA筛查可能漏诊的早孕期症状前胎儿,但临床有效性和效用需进一步研究确认,并需解决可及性、遗传咨询、伦理和政策等挑战。
要点
- 产前cfDNA筛查已扩展至亚染色体拷贝数变异,但显性单基因病筛查在普通产科人群未充分利用。
- 多基因panel产前cfDNA筛查可补充影像学和标准cfDNA筛查,有助早期发现症状前胎儿。
- 临床有效性和效用需进一步研究确认,需更大更多样化研究评估广泛适用性。
核心结论
- 多基因panel产前cfDNA筛查显性单基因病初步结果有前景,但需进一步研究确认其临床有效性和效用,并需更大更多样化研究评估广泛适用性。
研究设计与样本
- 本文为综述,回顾多基因panel产前cfDNA筛查显性单基因病的最新数据与经验。
主要发现
- 产前cfDNA筛查已从检测非整倍体扩展到亚染色体拷贝数变异。
- 显性单基因病常由新发变异引起,其在普通产科人群中的cfDNA筛查应用仍未充分利用。
- 整合全面cfDNA筛查可补充当前影像技术和标准产前cfDNA筛查,后者可能漏诊早孕期症状前显性单基因病胎儿。
临床怎么用
- 作者认为将全面cfDNA筛查整合入常规产前保健可补充影像学和标准cfDNA筛查。
- 作者指出成功采用扩展cfDNA筛查需严格检测设计、知情同意和稳健的遗传咨询。
- 作者指出需解决可及性、遗传咨询、伦理考虑和政策制定等关键挑战。
局限性
- 原文指出需进一步研究确认cfDNA筛查这些疾病的临床有效性和效用。
- 原文指出需更大和更多样化的研究评估该技术的更广泛适用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prenatal cell-free DNA (cfDNA) screening has advanced significantly, extending beyond detecting aneuploidies to sub-chromosomal copy number variations. However, its application for screening dominant single-gene conditions, often caused by de novo variants, remains underutilized in the general obstetric population. This study reviews recent data and experience on prenatal cfDNA screening for dominant monogenic conditions using multiple-gene panels, highlighting its potential to enhance early detection and management of genetic disorders. Integrating comprehensive cfDNA screening into routine prenatal care could complement current imaging techniques and standard prenatal cfDNA screening, which may overlook pre-symptomatic fetuses with dominant monogenic conditions in early gestation. Despite promising initial results, further research is needed to confirm the clinical validity and utility of cfDNA screening for these conditions. Larger and more diverse studies are necessary to assess the broader applicability of this technology. In addition, key challenges such as access, genetic counseling, ethical considerations, and policy development need to be addressed. A comprehensive approach, including rigorous test design, informed consent, and robust counseling, is essential for the successful adoption of expanded cfDNA screening, ultimately improving clinical outcomes.
引用
- Liao J, Xu N, Gao H, et al. Advances in Prenatal Cell-Free DNA Screening for Dominant Monogenic Conditions: A Review of Current Progress and Future Directions in Clinical Implementation. Prenat Diagn. 2025. PMID: 39865331. doi:10.1002/pd.6752
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。